KC startup’s bone cancer treatment for dogs earns ‘milestone’ USDA validation
January 25, 2024 | Startland News Staff
A decade of hard work by a veteran entrepreneur and her Olathe-based team has cleared a significant hurdle on the pathway to licensure as its first-in-class adoptive cell therapy for dog cancer gains a critical nod of approval from federal regulators.
ELIAS Animal Health, a leading companion animal cancer therapeutics company, recently announced that the U.S. Department of Agriculture Center for Veterinary Biologics determined its clinical trial data demonstrated a reasonable expectation of efficacy for the treatment of bone cancer in dogs.
“We are thrilled to achieve this important milestone with our first cancer product,” said Tammie Wahaus, CEO of ELIAS Animal Health. “I want to thank the pet owners who enrolled their dogs in the ECI-OSA-04 study, the veterinarians for their perseverance to complete the study during a pandemic, and my team for their tireless dedication. We are excited to bring this advanced personalized medicine to the veterinary market and provide a new tool in the fight against cancer.”
Founded in 2014, ELIAS Animal Health is a medical biotechnology company advancing novel targeted T cell-based immunotherapies for the treatment of canine cancers. Cancer is the leading cause of death in dogs over the age of two and represents a significant unmet medical need in veterinary medicine.
Validation by the USDA is an important step in advancing the solution, said Wahaus, a Pipeline Entrepreneur from the 2019 fellowship.
The company plans to raise a $10 million Series A round to support manufacturing expansion, commercial launch of its ELIAS Cancer Immunotherapy (ECI) product, and continued development of its product pipeline: including a novel oncolytic immunotherapy, a pilot study combining ECI with a conditionally approved checkpoint inhibitor, and a pilot study evaluating its adoptive cell therapy in large breed dogs using a sophisticated surgical technique to avoid amputation.
ELIAS Animal Health’s two-arm field safety and efficacy study was one of the largest clinical trials conducted in canine cancer and the first of its kind to evaluate a state-of-the-art adoptive cell therapy as a treatment for cancer in dogs, the company said. ECI works by conditioning the immune system to recognize a patient’s unique cancer, and then delivering an army of activated killer T cells to specifically target and attack those cancer cells.
Prior to commercial launch, which is expected later in 2024, ECI will continue to be available as an experimental biologic for veterinary use under ELIAS’s existing 9 CFR 103.3 authorization as the company finalizes the remaining regulatory actions to secure a first-in-class Autologous Prescription Product license.
Click here to read more about the journey of ELIAS Animal Health, one of Startland News’ Kansas City Startups to Watch in 2020.
2024 Startups to Watch
stats here
Related Posts on Startland News
KC seamstress reaffirms gender identities, provides confidence through compression garments
Every individual deserves to express how they feel on the inside through their outer appearance, Laura Treas shared; and clothing has the power to make that transition. “Fashion can appear to be so shallow, but we know that isn’t the case. Our undergarments give someone the look and silhouette on the outside that they feel…
KC inventor’s untimely death leaves legacy of fearlessness, unfinished vision
Paul Francis pioneered fitness tech for NASA, commercialized it with Bowflex, then raised $4 million on Kickstarter: How the OYO founder’s unexpected death this month cut his storied entrepreneurial journey short — but left a lasting impression on the people who worked alongside him. Former colleagues are remembering the late Paul Francis as a uniquely…
Pitches and peaches: Hy-Vee awards $30K piece of the $50K prize pie to family-run cobbler company
Denisha Jones sweetened Hy-Vee’s OpportUNITY Inclusive Business Summit and pitch competition this week with her ready-to-bake cobblers. Her pitch (and peaches) secured the $30,000 grand prize. “Every time Thanksgiving comes around, I always crave my grandmother’s cobbler. During the pandemic, I was unsuccessful in finding a cobbler as good as my grandmother’s, so I went…
Meet six newly funded startups Digital Sandbox KC is making more fundable tomorrow
Newly awarded funds are expected to help six more companies scale their fledgling startups past the proof-of-concept stage, said Jill Meyer, touting Digital Sandbox KC’s track record of making startups and their products more fundable once they’re built. “Digital Sandbox KC is one of the Kansas City metro’s rare early-stage funds and provides vital support…